Novartis completes the acquisition of CELLforCURE, expanding its global production capacity for innovative cell and gene therapies.

• CELLforCURE becomes a Novartis group company and joining network of cell and gene sites including Morris Plains (USA) and Stein (Switzerland).

• This acquisition strengthens CAR-T cell therapy manufacturing capacity with potential to expand to other cell and gene therapies in Novartis pipeline.

• The acquisition follows the partnership signed between the two companies in July 2018.

 
×